ARTES Biotech and Burnet Institute join forces to develop Hep C vaccine : thepharmaletter

as informed in thepharmaletter

ARTES Biotech and Burnet Institute join forces to develop Hep C vaccine

ARTES Biotech and Burnet Institute join forces to develop Hep C vaccine

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.Please login, take a free trial or subscribe in order to continue reading.A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.


let alone pharmabiz

ARTES, Burnet Institute partner to develop novel hepatitis C vaccine

ARTES, Burnet Institute partner to develop novel hepatitis C vaccine

ARTES Biotechnology and Burnet Institute have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis C virus (HCV).An HCV vaccine is urgently needed to prevent re-infection in people treated through antiviral therapies and reverse the high global mortality rates from infection-related liver cirrhosis or liver cancer, estimated by the World Health Organization (WHO) to be more than 500,000 people each year.More than 130 million people globally are carriers of HCV, a blood-borne virus.


by the same token on insidehalton

Oakville resident helps develop 'promising' chlamydia vaccine

Oakville resident helps develop 'promising' chlamydia vaccine

Oakville resident Dr. James Mahony is among researchers at McMaster University in Hamilton who are on the verge of developing a vaccine for chlamydia.Related Stories Chlamydia and flu cases on the rise...The sexually-transmitted disease (STD) impacts 113 million people around the world each year and can cause women to become infertile if left untreated.